Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyophilized plasma is a freeze-dried human plasma product developed by HemCon Medical Technologies, primarily under contract for the US Army. It is intended for the emergency treatment of hemorrhage and coagulation factor deficiencies in environments where refrigeration for fresh frozen plasma (FFP) is unavailable. The product is created by separating plasma from whole blood and undergoing a lyophilization process to create a stable powder that can be reconstituted and administered intravenously. Clinical data from a Phase 1 study indicated that the product maintains essential coagulation factor levels and is safe for infusion. Development ceased as HemCon Medical Technologies is no longer in business.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lyophilized plasma.